Abstracts Archive - Page 816 of 2425 - ACR Meeting Abstracts

Abstract Number: 864 • 2019 ACR/ARP Annual Meeting
Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter¹, Robert Spiera ¹, Dana Orange ², Cynthia Magro ³, Yaxia Zhang ⁴, Jackie Finik ⁵ and Jessica Gordon ¹, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Weill Cornell Medicine, New York, ⁴Hospital for Special Surgery, New York, ⁵Hospital for Special Surgery, New York, NY, New York, NY
Background/Purpose: The Combined Response Index in Systemic Sclerosis (CRISS) is a composite outcome measure provisionally endorsed by the American College of Rheumatology for use in…
Abstract Number: 865 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert Spiera¹, Laura Hummers ², Lorinda Chung ³, Tracy Frech ⁴, Robyn Domsic ⁵, Vivien Hsu ⁶, Daniel Furst ⁷, Jessica Gordon ¹, Madeline Myers ⁸, Robert W Simms ⁹, Elizabeth Lee ¹⁰, Scott Constantine ¹⁰, Nancy Dgetluck ¹⁰, Bradley Bloom ¹⁰ and Barbara White ¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ³Stanford, Palo Alto, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, ⁷University of California, Los Angeles, CA, ⁸University of Texas, Houston, Houston, TX, ⁹Boston University, Boston, MA, ¹⁰Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses and limits fibrosis in animal models…
Abstract Number: 866 • 2019 ACR/ARP Annual Meeting
Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease
Edward Stern ¹, Lauren Host ¹, K. Jane Escott ², Peter Gilmour ², Ivy Wanjiku ³, Rachel Ochiel ³, Aine Burns ¹, Robert Unwin ¹, Voon Ong ⁴ and Christopher Denton⁵, ¹University College London, London, United Kingdom, ²AstraZeneca, London, United Kingdom, ³Royal Free Hospital, London, United Kingdom, ⁴UCL Medical School, Royal Free Campus, London, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) causes scleroderma renal crisis (SRC) and chronic kidney disease (CKD). A previous open label trial of bosentan suggested possible benefit for…
Abstract Number: 867 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Mark Nicolls¹, David Badesch ², Lorinda Chung ³, Robyn Domsic ⁴, Thomas Medsger ⁵, Ashley Pinckney ⁶, Lynette Keyes-Elstein ⁶, Carla D'Aveta ⁶, Meagan Spychala ⁶, R James White ⁷, Paul Hassoun ⁸, Fernando Torres ⁹, Jerry Molitor ¹⁰, Dinesh Khanna ¹¹, Holden Maeker ¹², Beverly Welch ¹³, Ellen Goldmuntz ¹⁴, Roham Zamanian ¹ and -- On Behalf of ASC01 Investigators ¹⁵, ¹Stanford University, Stanford, ²University of Colorado, Denver, ³Stanford University, Palo Alto, CA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, ⁶Rho Federal Systems, Durham, ⁷University of Rochester, Rochester, NY, ⁸Johns Hopkins School of Medicine, Baltimore, ⁹UT Southwestern, Dallas, ¹⁰University of Minnesota, University of Minnesota, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²Stanford, Stanford, ¹³National Institute of Allergy and Infectious Diseases, NIH, Bethesda, ¹⁴NIAID, Washingto, DC, ¹⁵---, USA
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have strongly implicated immune dysregulation and B cell…
Abstract Number: 868 • 2019 ACR/ARP Annual Meeting
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study
Robyn Domsic¹, Maureen Laffoon ¹, Balasubramani Goundappa ², Thomas Medsger ¹, Robert Lafyatis ¹ and Steven Wisniewski ¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh Epidemiology Data Center, Pittsburgh, PA
Background/Purpose: Statins have pleiotropic effects felt to influence in their beneficial cardiovascular effects. These include increased nitric oxide production and improved endothelial function, modulation of…
Abstract Number: 869 • 2019 ACR/ARP Annual Meeting
Clinical Manifestations of Patients with Eosinophilic Granulomatosis with Polyangiitis in a Large North American Cohort
Irena Doubelt¹, David Cuthbertson ², Simon Carette ¹, Nader A. Khalidi ³, Curry L. Koening ⁴, Carol Langford ⁵, Carol A. McAlear ⁶, Larry W. Moreland ⁷, Paul Monach ⁸, Philip Seo ⁹, Ulrich Specks ¹⁰, Antoine Sreih ¹¹, Steven Ytterberg ¹⁰, Peter A. Merkel ¹², Christian Pagnoux ¹ and VCRC Vasculitis Clinical Research Consortium ¹³, ¹Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ²University of South Florida, Tampa, FL, ³McMaster University, Hamilton, ON, Canada, ⁴University of Utah Hospital, Salt Lake City, UT, ⁵Cleveland Clinic, Cleveland, OH, ⁶University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Johns Hopkins Medicine, Baltimore, MD, ¹⁰Mayo Clinic College of Medicine, Rochester, MN, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Univeristy of Pennsylvania, Philadelphia, PA, ¹³University of Pennsylvania, Division of Rheumatology, philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, systemic necrotizing small-vessel vasculitis, with only a few published North American series. This project aimed to…
Abstract Number: 870 • 2019 ACR/ARP Annual Meeting
Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)
Alice Canzian ¹, Nils Venhoff ², Silvia Sartorelli ³, Anne-Marie Ruppert ⁴, Matthieu Groh ⁵, Camille Taille ⁶, Virginie Rieu ⁷, Perrine Smets ⁷, François Maurier ⁸, Nicolas Girszyn ⁹, Maxime Samson ¹⁰, Claire de Moreuil ¹¹, Grégory Pugnet ¹², Xavier Delbrel ¹³, Jean-Emmanuel Kahn ¹⁴, Xavier Puéchal for the French Vasculitis Study Group ¹⁵, Giacomo Emmi ¹⁶, Loic Guillevin ¹⁵, Lorenzo Dagna ¹⁷, Jens Thiel ², Augusto Vaglio ¹⁸ and Benjamin Terrier¹⁵, ¹Cochin Hospital, Paris, France, ²Clinic for Rheumatology and Clinical Immunology, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany, ³Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ⁴Tenon Hospital, Paris, France, ⁵Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, Suresnes, France, ⁶Bichat Hospital, Paris, France, ⁷CHU, Clermont-Ferrand, France, ⁸Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ⁹CHU, Rouen, France, ¹⁰Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ¹¹CHU Brest, Brest, France, ¹²CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹³CH, Pau, France, ¹⁴APHP, Boulogne Billancourt, France, ¹⁵National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ¹⁶Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy, Florence, Italy, ¹⁷Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ¹⁸Nephrology Unit, Parma University Hospital, Parma, Italy, Nephrology Unit, Parma University Hospital, Parma, Italy, Italy
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg–Strauss syndrome), is characterized by small-vessel necrotizing vasculitis, and blood and tissue eosinophilia in asthmatic individuals. Glucocorticoids (GCs)…
Abstract Number: 871 • 2019 ACR/ARP Annual Meeting
ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry
Zachary Wallace¹, Huifeng Yun ², Jeffrey Curtis ², Shuo Yang ², Lang Chen ², John Stone ³ and Hyon K. Choi ⁴, ¹Massachusetts General Hospital, Boston, ²University of Alabama at Birmingham, Birmingham, AL, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: The management of ANCA-associated vasculitis (AAV) evolved substantially in recent years because of evidence supporting the efficacy of various treatment regimens. As such, treatment…
Abstract Number: 872 • 2019 ACR/ARP Annual Meeting
Granulomatosis with Polyangiitis Sustained Remission Off-Therapy: Data from the French Vasculitis Study Group Registry
Xavier Puéchal for the French Vasculitis Study Group¹, Michele Iudici ², Christian Pagnoux ³, Alexandre Karras ⁴, Pascal Cohen ¹, François Maurier ⁵, Thomas Quémeneur ⁶, François Lifermann ⁷, Mohamed Hamidou ⁸, Luc Mouthon ¹, Benjamin Terrier ¹ and Loic Guillevin ¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ²National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin and Geneva Switzerland, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin and Toronto Canada, Paris, France, ⁴Paris HEGP, Paris, France, ⁵Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ⁶CH Valenciennes, Valenciennes, France, ⁷CH Dax, Dax, France, ⁸CHU Nantes, Nantes, France
Background/Purpose: Data on granulomatosis with polyangiitis (GPA) sustained remission off-therapy (SROT) are limited and it is unknown whether disease characteristics or treatment regimen may affect…
Abstract Number: 873 • 2019 ACR/ARP Annual Meeting
Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database
Sebastian E. Sattui¹, Zafir Abutalib ², Jackie Finik ² and Robert Spiera ³, ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Pulmonary involvement, including pulmonary vascular disease and interstitial lung disease can be an important cause of morbidity and even mortality in patients with primary…
Abstract Number: 874 • 2019 ACR/ARP Annual Meeting
Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features
Iazsmin Ventura¹, Anisha Dua ², Ayodeji Adegunsoye ³, Mary Strek ³, James Curran ¹, Alexandra Weiss ¹ and Jonathan Chung ¹, ¹University of Chicago, Chicago, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Chicago, Department of Pulmonary and Critical Care, Chicago
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) have been identified in patients who have pneumonia without a diagnosis of ANCA-associated vasculitis (AAV). These patients are presently categorized…
Abstract Number: 875 • 2019 ACR/ARP Annual Meeting
Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial
Tim Pelle¹, Karen Bevers ¹, Job van der Palen ², Frank van den Hoogen ³ and Cornelia van den Ende ¹, ¹Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ²Department of research methodology, Univeristy of Twente, Enschede, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Self-management is of paramount importance in non-surgical treatment of knee/hip osteoarthritis (OA). Modern technologies offer the possibility to support self-management 24/7. We developed an…
Abstract Number: 876 • 2019 ACR/ARP Annual Meeting
“When You Read This, You Really Feel Old!” Perspectives of Young People with Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study
Erika Mosor¹, Paul Studenic ¹, Alessia Alunno ², Ivan Padjen ³, Wendy Olsder ⁴, Sofia Ramiro ⁵, Ilaria Bini ⁶, Nele Caeyers ⁷, Laure Gossec ⁸, Marios Kouloumas ⁹, Elena Nikiphorou ¹⁰, Simon Stones ¹¹, Tanita Wilhelmer ¹² and Tanja Stamm ¹, ¹Medical University of Vienna, Vienna, Austria, ²Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ³UHC Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, ⁴Patient Research Partner, Amsterdam, Netherlands, ⁵Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ⁶ANMAR Young Patient Advocate, Avellino, Italy, ⁷Patient Research Partner, Brussels, Belgium, ⁸Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁹Cyprus League Against Rheumatism, Nicosia, Cyprus, ¹⁰King's College London, London, United Kingdom, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Österreichische Rheumaliga, Bregenz, Austria
Background/Purpose: Although patient-reported outcome measures (PROMs) are extensively used in clinical practice and research, it is unclear whether the most commonly used instruments adequately cover…
Abstract Number: 877 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Patients’ Perspectives on Tapering of Biologics: A Qualitative Study
Jack Chan ¹, Lisa Stamp², Nicola Liebergreen ¹, Henry Ndukwe ¹, Carlo Marra ¹ and Gareth Treharne ¹, ¹University of Otago, Dunedin, New Zealand, ²University of Otago, Christchurch, Christchurch, Canterbury, New Zealand
Background/Purpose: Tapering of biologics is now recommended in the management of people with RA in sustained remission.1 Clinical studies have shown some RA patients can…
Abstract Number: 878 • 2019 ACR/ARP Annual Meeting
The Association of Serum Magnesium with Chondrocalcinosis and Osteoarthritis
Devyani Misra¹, Xianbang Sun ², Michael Nevitt ³, Beth Lewis ⁴, James Torner ⁵, Tuhina Neogi ², Alice Lichtenstein ⁶, Nirupa Matthan ⁶ and David Felson ⁷, ¹Beth Israel Deaconess Medical Center, Waban, MA, ²Boston University School of Medicine, Boston, MA, ³University of California at San Francisco, San Francisco, CA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Iowa at Iowa City, Iowa City, ⁶Tufts University, Boston, MA, ⁷Boston University School of Medicine, Department of Rheumatology, Boston
Background/Purpose: High serum magnesium (Mg) may have anti-inflammatory effects and prevents the release of extracellular pyrophosphate, inhibiting CPP deposition. Cross-sectional data has linked low serum…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].